Advanced searches left 3/3

Car T Cell Therapy - Springer Nature

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

B-cell maturation antigen therapy, Chimeric antigen receptor T-cell therapy, has shown promising results in autoimmune diseases and may be promising as novel therapy for relapsed/refractory neuromyelitis optica spectrum disorder. Hematologic toxic effects were the most common activities of grade 3 or higher. Seven patients developed infections, but no grade 4 infections were present, but no grade 4 infections were present. In all patients, Cytokine release syndrome was identified, but no events of grade 1 or 2 were observed. 11 patients had no relapse during the follow-up to a median 5. 5 months, no relapse was recorded; all patients reported improvements in disabilities and quality-of-life outcomes; 11 patients had no relapse; 11 patients had no deterioration; and quality-of-life indicators improved; 11 patients' u2019 AQP-4 antibodies in serum showed a decline trend by the cutoff date; 11 patients had no relapse; all patients reported improvements in disabilities; and quality-of-based In summary, CAR T-cell therapy provides a scalable safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD. CAR T-BCMA infusion in patients with other neuro-inflammatory disorders is also ongoing in order to determine the safety and effectiveness of the drug in patients with other neuro-inflammatory disorders.

Source link: https://doi.org/10.1038/s41392-022-01278-3


Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

In clinical trials involving patients with solid tumors, Chimeric antigen receptor T cell therapies have resulted in on-target, off-tumour toxicities. Patients need rigorous preclinical evaluations of the risks of OTOT and the development of control protocols capable of controlling CAR T cell activity. Certain B cell malignancies can be treated by therapies that contain chimeric antigen receptors specific for CD19 or B cell maturation antigen receptors. We review recent clinical evidence of OTOT with CAR T cells in the treatment of solid tumours in solid tumors and discuss the use of preclinical mouse models in predicting clinical OTOT. In addition, we discuss control tactics that may be used to reduce clinical OTOT after cell transplantation, including banning or eliminating CAR T cell proliferation, exogenous monitoring of CAR expression, and local administration of CAR T cells. Patients with relapsed and/or refractory B cell malignancies can be treated with Chimeric antigen receptor T cells, which can be partially due to the ability to detect B cell-specific antigens. However, CAR T cells targeting solid tumor antigens are likely to be at a higher risk of on-target, off-target toxicity. Here, the authors review the available OTOT results in the context of CAR T cells targeting solid tumour antigens and offering novel CAR T cell designs that could help avoid such toxicities.

Source link: https://doi.org/10.1038/s41571-022-00704-3


Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Background: Both tumor and non-malignant lymphoid tissue for Progression Free Survival and Overall Survival in patients with refractory large B-cell lymphoma undergoing Chimeric Antigen Receptor T-cell therapy is available in both tumor and non-malignant lymphoid tissue. Methods A single-center prospective review of 16 r/r LBCL patients undergoing CD19-targeted CAR T-cell therapy found no results. Maximum Standardized Uptake Value, mean SUV, Metabolic Tumor Volume, Tumor Lesion Glycolysis, total structural tumor burden, and mean Apparent Diffusion Coefficient were among Tumor metrics reported in this article. MTV 39. 5 ml, u22641. 35 Ml, u0394 ml, u22641. 35Ml, u23641. 35 and u22641. 35, according to Kaplan-Meier's review, a longer PFS was achieved for patients with pre-therapy MTV u22641. 35 and u22641. 35. Pre-therapy bone marrow SUV_mean was compared to PFS p 0. 05. Conclusions MTV, tumor ADC_mean, and FDG uptake in bone marrow unaffected by tumor infiltration are all potential PET/MR metrics for predicting PFS and OS in r/r LBCL treated with CAR T-cells.

Source link: https://doi.org/10.1186/s40644-022-00513-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions